{
    "nct_id": "NCT01117181",
    "title": "Apathy in Dementia Methylphenidate Trial (ADMET)",
    "status": "COMPLETED",
    "last_update_time": "2018-06-07",
    "description_brief": "The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial that will examine the efficacy and safety of methylphenidate for the treatment of clinically significant apathy in patients with Alzheimer's dementia.",
    "description_detailed": "The Apathy in Dementia Methylphenidate Trial (ADMET), funded by the National Institute of Aging, is a Phase II, placebo-controlled, masked, 3-center randomized clinical trial. ADMET will enroll 60 patients with Alzheimer's disease (AD) and significant apathy from outpatient, nursing home, and assisted living facilities along with their primary caregiver. Eligible and willing patients will be randomly assigned to methylphenidate (20 mg per day) or placebo. At baseline and each in-person follow-up visit, all caregivers and patients will be provided with a standardized psychosocial intervention consisting of a counseling session, provision of educational materials, and 24-hour availability for crises. Efficacy and safety outcomes will be measured at baseline and at in-person follow-up visits at 2, 4, and 6 weeks following randomization. Telephone contact will take place at 1, 3, and 5 weeks after randomization.\n\nADMET has 80% power to detect a difference of at least 3.3 in change in the Apathy Evaluation Scale scores between the two treatment groups. It also has 80% power to detect an absolute difference of 35% or more in the change in the proportion of study participants improving on te Clinical Global Impression of Change, given that 20% to 305 of participants in the placebo group show improvement.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "recruitmentDetails": "Clinical center recruited from established outpatient clinics, from living facilities, by local physicians, and from targeted advertisements in local media. The recruitment period started June 2010 and ended October 2011.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Methylphenidate",
                    "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention"
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "matching placebo and psychosocial intervention"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "29"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "31"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "28"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Methylphenidate",
                    "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention"
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "matching placebo and psychosocial intervention"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "29"
                        },
                        {
                            "groupId": "BG001",
                            "value": "31"
                        },
                        {
                            "groupId": "BG002",
                            "value": "60"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "6"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "54"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "78",
                                            "spread": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "75",
                                            "spread": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "76",
                                            "spread": "8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "37"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "23"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "41"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Canada",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Apathy Evaluation Scale (AES)",
                    "description": "Change in score of Apathy Evaluation Scale from baseline to 6 weeks; the minimum score is 18; the maximum score is 72. Higher scores indicate more severe apathy.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "baseline to 6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.9",
                                            "spread": "1.5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.6",
                                            "spread": "1.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change",
                    "description": "Proportion of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 weeks; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: \"marked worsening\"(7), \"moderate worsening\" (6), \"minimal worsening\"(5), \"no change\"(4), \"minimal improvement\"(3), \"moderate improvement\"(2), \"marked improvement\"(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "percentage of participants who improve",
                    "timeFrame": "baseline to 6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Digit Span",
                    "description": "Change in Digit Span from baseline to 6 weeks. The Wechsler Adult Intelligence Scale - Revised Digit Span is used to assess auditory attention and working memory. Both forward and backward span is assessed. Both tests consist of six number sequences that the psychometrist reads aloud one at a time. After each sequence is read, the participant must repeat the digits back in the same (forward) or reverse (backward) order. Scores range from 0 to 16, with higher numbers indicate better functioning.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "baseline and 6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "26"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.46",
                                            "spread": "1.55"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.07",
                                            "spread": "1.25"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mini-Mental State Exam (MMSE)",
                    "description": "Change in Mini-Mental State Exam score from baseline to 6 weeks; this cognitive test estimates of dementia severity. Domains included orientation, memory, working memory, naming, following verbal and written commands, spontaneously writing a sentence, and copying two overlapping pentagons. The minimum MMSE score is 0; the maximum MMSE score is 30. Lower MMSE scores indicate more severe cognitive impairment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "baseline and 6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.3",
                                            "spread": "0.6"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.3",
                                            "spread": "0.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI): Apathy Subscale",
                    "description": "Change from baseline to 6 weeks in neuropsychiatric symptoms in apathy subscore. Frequency (ranges from 1=occasionally, less than once/week to 4 = very frequently, once or more/day or continuously) and severity (1=mild, 2=moderate, 3=severe) scales are scored based on responses from an informed caregiver involved in the patient's life. To obtain the NPI score, the severity score is multiplied by the frequency score. Range is 0 to 12. Larger numbers indicate more severe behavioral disturbance.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "units on a scale",
                    "timeFrame": "baseline to week 6",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "matching placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-4.4",
                                            "spread": "0.6"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-2.6",
                                            "spread": "0.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Vital Status",
                    "description": "vital status as measured by death",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants who died",
                    "timeFrame": "vital status at 6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "matching placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Electrolytes",
                    "description": "Percent of participants with abnormal electrolyte values at 6 weeks as assessed by local laboratory",
                    "populationDescription": "One patient in the active group completed all visit 6 assessments except for the blood collection for the electrolyte sample. This patient refused this procedure.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "percentage of participants",
                    "timeFrame": "6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "27"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Sodium",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.70"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Potassium",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14.81"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.34"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Chloride",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.41"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.34"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Bicarbonate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.41"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.34"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Electrocardiogram (ECG)",
                    "description": "Abnormal electrocardiogram results at 6 weeks",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants with abnormal ECG",
                    "timeFrame": "6 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Methylphenidate",
                            "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "matching placebo and psychosocial intervention"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "20"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "treatment period (i.e., 6 weeks)",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Methylphenidate",
                    "description": "Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 29,
                    "otherNumAffected": 29,
                    "otherNumAtRisk": 29
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "matching placebo and psychosocial intervention",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 31,
                    "otherNumAffected": 29,
                    "otherNumAtRisk": 31
                }
            ],
            "seriousEvents": [
                {
                    "term": "abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "drop in hemoglobin",
                    "organSystem": "Blood and lymphatic system disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "agitation",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 13,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 10,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "weight loss",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "notes": "greater than 2% at week 6",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Aggressive behavior or hostility",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Angina",
                    "organSystem": "Cardiac disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Anorexia",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 14,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Blood pressure changes",
                    "organSystem": "Vascular disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Blurry vision or eyesight changes",
                    "organSystem": "Eye disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Depressed appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 8,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Depressed mood",
                    "organSystem": "Psychiatric disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 12,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 12,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Distractibility",
                    "organSystem": "Social circumstances",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 8,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Ear and labyrinth disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Drowsiness",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 13,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Dry mouth",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Dyskinesia",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Hair loss",
                    "organSystem": "Endocrine disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Hyperactivity",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Impaired learning",
                    "organSystem": "Social circumstances",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Skin rash, redness, or inflammation",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 29
                        }
                    ]
                },
                {
                    "term": "Tics (motor or verbal)",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 29
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Anne Casper, MA",
                "organization": "Johns Hopkins",
                "email": "ashankli@jhsph.edu",
                "phone": "410-955-8183"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "methylphenidate"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial (ADMET) tests methylphenidate for clinically significant apathy in patients with Alzheimer's disease. Apathy is a neuropsychiatric/behavioral symptom; the objective is symptom reduction (apathy scales, global impression), not to modify Alzheimer pathology (amyloid/tau). \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Act: Key extracted trial details \u2014 Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, randomized, placebo-controlled study of methylphenidate vs placebo enrolling AD patients with clinically significant apathy; primary outcomes assess change in apathy (AES, NPI apathy, ADCS-CGIC). ADMET and the larger follow-up ADMET2 used methylphenidate dosing (target ~20 mg/day; ADMET2: 10 mg twice daily) and demonstrated improvement in apathy measures. \ue200cite\ue202turn0search4\ue202turn0search1\ue202turn0search7\ue201",
        "Reflect: Classification rationale \u2014 Although methylphenidate is a small-molecule stimulant that increases dopaminergic/noradrenergic signaling, in this trial it is used to alleviate a behavioral/neuropsychiatric symptom (apathy). By the category definitions, this fits 'neuropsychiatric symptom improvement' rather than 'disease-targeted' or 'cognitive enhancer' (the intended effect is symptomatic relief of apathy). Note: if one categorized solely by drug chemistry (small molecule) there could be ambiguity, but the trial purpose and outcomes determine the correct category here. \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Web search results (selected, load-bearing): (1) ADMET randomized, placebo-controlled 6-week trial report and description (safety & efficacy objectives). \ue200cite\ue202turn0search4\ue201 (2) Preliminary/presentation materials describing ADMET rationale (methylphenidate as dopaminergic stimulant for apathy). \ue200cite\ue202turn0search0\ue201 (3) ADMET2 protocol and registration (phase III, 6-month, methylphenidate 20 mg/day vs placebo). \ue200cite\ue202turn0search1\ue201 (4) ADMET2 published results reporting a small-to-moderate benefit on apathy (NPI-apathy decrease) and acceptable safety. \ue200cite\ue202turn0search7\ue202turn0search2\ue201 (5) Safety-focused report from ADMET discussing adverse events observed in the trial. \ue200cite\ue202turn0search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: ADMET tests methylphenidate, a stimulant that increases dopaminergic and noradrenergic signaling, to relieve apathy \u2014 a neuropsychiatric/symptomatic outcome rather than a disease-modifying (amyloid/tau) intervention. This implicates modulation of neurotransmitter systems.",
        "Act: Extracted details \u2014 Trial: Apathy in Dementia Methylphenidate Trial (ADMET). Intervention: methylphenidate (small-molecule stimulant; increases extracellular dopamine and norepinephrine via transporter blockade). Purpose/outcomes: symptomatic reduction of apathy (AES, NPI-apathy, ADCS-CGIC); dosing in ADMET/ADMET2 ~10 mg twice daily (target ~20 mg/day). These facts point to a neurotransmitter-targeted symptomatic treatment.",
        "Reflect: Classification check \u2014 CADRO category D (Neurotransmitter Receptors) is the best match because the intervention modulates neurotransmitter systems (dopamine/norepinephrine) to treat a behavioral symptom. Although methylphenidate acts primarily on transporters rather than receptor proteins, CADRO\u2019s 'Neurotransmitter' grouping is the most appropriate given the mechanism and symptomatic aim; it is not disease-modifying (rules out A/B/I/etc.) and not multi-target in the CADRO sense. If strict transporter-only mapping were required, one could argue for a more specific subcategory, but within CADRO labels D is correct.",
        "Web search results (as provided / load-bearing sources): (1) ADMET randomized, placebo-controlled 6-week trial report and description (safety & efficacy objectives). (2) Preliminary/presentation materials describing ADMET rationale (methylphenidate as dopaminergic stimulant for apathy). (3) ADMET2 protocol and registration (phase III/longer, methylphenidate ~20 mg/day vs placebo). (4) ADMET2 published results reporting small-to-moderate benefit on apathy (NPI-apathy decrease) and acceptable safety. (5) Safety-focused report from ADMET discussing adverse events observed in the trial.)"
    ]
}